Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE

被引:159
作者
Alonso, D
Dorronsoro, I
Rubio, L
Muñoz, P
García-Palomero, E
Del Monte, M
Bidon-Chanal, A
Orozco, M
Luque, FJ
Castro, A
Medina, M
Martínez, A
机构
[1] Neuropharm SA, Madrid 28760, Spain
[2] Univ Barcelona, Fac Farm, Dept Fisicoquim, Barcelona 08028, Spain
[3] Univ Barcelona, Fac Quim, Dept Bioquim & Biol Mol, Barcelona 08028, Spain
关键词
acetylcholinesterase inhibitors; tacrine; donepezil; Alzheimer's disease;
D O I
10.1016/j.bmc.2005.09.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A new series of donepezil-tacrine hybrid related derivatives have been synthesised as dual acetylcholinesterase inhibitors that could bind simultaneously to the peripheral and catalytic sites of the enzyme. These new hybrids combined a tacrine, 6-chlorotacrine or acridine unit as catalytic binding site and indanone (the heterocycle present in donepezil) or phthalimide moiety as peripheral binding site of the enzyme, connected through a different linker tether length. One of the synthesised compounds emerged as a potent and selective AChE inhibitor, which is able to displace propidium in a competition assay. These results seem to confirm the ability of this inhibitor to bind simultaneously to both sites of the enzyme and make it a promising lead for developing disease-modifying drugs for the future treatment of Alzheimer's disease. To gain insight into the molecular determinants that modulate the inhibitory activity of these compounds, a molecular modelling study was performed to explore their binding to the enzyme. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6588 / 6597
页数:10
相关论文
共 50 条
[1]   Rational Design of Reversible Acetylcholinesterase Inhibitors [J].
Barril, X. ;
Kalko, S. G. ;
Orozco, M. ;
Luque, F. J. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (01) :27-36
[2]   Predicting relative binding free energies of tacrine-huperzine A hybrids as inhibitors of acetylcholinesterase [J].
Barril, X ;
Orozco, M ;
Luque, FJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) :5110-5119
[3]   Back door opening implied by the crystal structure of a carbamoylated acetylcholinesterase [J].
Bartolucci, C ;
Perola, E ;
Cellai, L ;
Brufani, M ;
Lamba, D .
BIOCHEMISTRY, 1999, 38 (18) :5714-5719
[4]  
Bayer TA, 2001, BRAIN PATHOL, V11, P1
[5]   A WELL-BEHAVED ELECTROSTATIC POTENTIAL BASED METHOD USING CHARGE RESTRAINTS FOR DERIVING ATOMIC CHARGES - THE RESP MODEL [J].
BAYLY, CI ;
CIEPLAK, P ;
CORNELL, WD ;
KOLLMAN, PA .
JOURNAL OF PHYSICAL CHEMISTRY, 1993, 97 (40) :10269-10280
[6]   Evidence for a noncholinergic function of acetylcholinesterase during development of chicken retina as shown by fasciculin [J].
Blasina, MF ;
Faria, AC ;
Gardino, PF ;
Hokoc, JN ;
Almeida, OMMS ;
de Mello, FG ;
Arruti, C ;
Dajas, F .
CELL AND TISSUE RESEARCH, 2000, 299 (02) :173-184
[7]   Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-β aggregation [J].
Bolognesi, ML ;
Andrisano, V ;
Bartolini, M ;
Banzi, R ;
Melchiorre, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :24-27
[8]   Brain acetylcholinesterase promotes amyloid-β-peptide aggregation but does not hydrolyze amyloid precursor protein peptides [J].
Campos, EO ;
Alvarez, A ;
Inestrosa, NC .
NEUROCHEMICAL RESEARCH, 1998, 23 (02) :135-140
[9]   New tacrine-huperzine A hybrids (huprines):: Highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease [J].
Camps, P ;
El Achab, R ;
Morral, J ;
Muñoz-Torrero, D ;
Badia, A ;
Baños, JE ;
Vivas, NM ;
Barril, X ;
Orozco, M ;
Luque, FJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (24) :4657-4666
[10]   Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands.: Development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties [J].
Cappelli, A ;
Gallelli, A ;
Manini, M ;
Anzini, M ;
Mennuni, L ;
Makovec, F ;
Menziani, MC ;
Alcaro, S ;
Ortuso, F ;
Vomero, S .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) :3564-3575